Cellular and humoral response to the fourth BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL.


Journal

European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985

Informations de publication

Date de publication:
Jan 2023
Historique:
revised: 04 10 2022
received: 05 09 2022
accepted: 06 10 2022
pubmed: 9 10 2022
medline: 7 12 2022
entrez: 8 10 2022
Statut: ppublish

Résumé

We assessed the humoral and cellular response to the fourth BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL. A total of 67 patients with CLL and 85 age matched controls tested for serologic response and pseudo-neutralization assay. We also tested the functional T-cell response by interferon gamma (IFNγ) to spike protein in 26 patients. Two weeks after the fourth vaccine antibody serologic response was evident in 37 (55.2%) patients with CLL, 20 /22 (91%) of treatment naïve, and 9/32 (28%) patients with ongoing therapy, compared with 100% serologic response in age matched controls. The antibody titer increased by 10-fold in patients with CLL, however, still 88-folds lower than age matched controls. Predictors of better chances of post fourth vaccination serologic response were previous positive serologies after second, third, and pre-fourth vaccination, neutralizing assay, and treatment naïve patients. T-cell response improved from 42.3% before the fourth vaccine to 84.6% 2 weeks afterwards. During the time period of 3 months after the fourth vaccination, 14 patients (21%) developed COVID-19 infection, all recovered uneventfully. Our data demonstrate that fourth SARS-CoV-2 vaccination improves serologic response in patients with CLL to a lesser extent than healthy controls and induces functional T-cell response.

Identifiants

pubmed: 36208015
doi: 10.1111/ejh.13878
pmc: PMC9874468
doi:

Substances chimiques

COVID-19 Vaccines 0
RNA, Messenger 0
BNT162 Vaccine 0
Antibodies, Viral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

99-108

Informations de copyright

© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Blood. 2020 Sep 3;136(10):1134-1143
pubmed: 32688395
Blood. 2022 Feb 3;139(5):678-685
pubmed: 34861036
MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):146-152
pubmed: 35085225
Hematol Oncol. 2021 Oct;39(4):570-574
pubmed: 34258787
Cancer Cell. 2022 Jun 13;40(6):584-586
pubmed: 35588735
Lancet Reg Health Eur. 2021 Aug;7:100150
pubmed: 34250518
Leukemia. 2021 Dec;35(12):3444-3454
pubmed: 34725454
N Engl J Med. 2022 Apr 7;386(14):1377-1380
pubmed: 35297591
N Engl J Med. 2021 May 20;384(20):1970
pubmed: 33882227
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
Nat Med. 2021 Nov;27(11):2032-2040
pubmed: 34588689
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
Leukemia. 2020 Nov;34(11):3047-3049
pubmed: 32855439
Nat Med. 2021 Jul;27(7):1280-1289
pubmed: 34017137
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
N Engl J Med. 2022 May 5;386(18):1712-1720
pubmed: 35381126
Blood Adv. 2022 Jan 11;6(1):148-151
pubmed: 34614513
Blood. 2021 Nov 4;138(18):1768-1773
pubmed: 34297826
Cell Mol Immunol. 2021 Oct;18(10):2307-2312
pubmed: 34471260
Blood. 2018 Jun 21;131(25):2745-2760
pubmed: 29540348
Viruses. 2022 Feb 08;14(2):
pubmed: 35215940
Br J Haematol. 2022 Apr;197(1):41-51
pubmed: 34962656
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Leukemia. 2021 Sep;35(9):2727-2730
pubmed: 34376803
Blood. 2015 Jul 30;126(5):573-81
pubmed: 26084672
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
Eur J Haematol. 2023 Jan;110(1):99-108
pubmed: 36208015
Haematologica. 2022 Mar 01;107(3):625-634
pubmed: 34320789
N Engl J Med. 2022 Apr 28;386(17):1603-1614
pubmed: 35417631
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Lancet Respir Med. 2021 Sep;9(9):999-1009
pubmed: 34224675
Leukemia. 2022 Feb;36(2):476-481
pubmed: 34564699
Blood Adv. 2022 Mar 22;6(6):1671-1683
pubmed: 35073571

Auteurs

Ohad Benjamini (O)

Hematology Division, Chaim Sheba Medical Centre, Tel-Hashomer, Israel.
Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.

Rotem Gershon (R)

Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.

Erez Bar-Haim (E)

Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona, Israel.

Yaniv Lustig (Y)

Central Virology Laboratory, Ministry of Health and Chaim Sheba Medical Center, Tel-Hashomer, Israel.

Hila Cohen (H)

Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona, Israel.

Ram Doolman (R)

The Dworman Automated-Mega Laboratory, Sheba Medical Center, Tel-Hashomer, Israel.

Meirav Kedmi (M)

Hematology Division, Chaim Sheba Medical Centre, Tel-Hashomer, Israel.
Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
The Mina and Everard Goodman Faculty of Life Science, Bar-Ilan University, Ramat-Gan, Israel.

Elena Ribakovsky (E)

Hematology Division, Chaim Sheba Medical Centre, Tel-Hashomer, Israel.

Abraham Kneller (A)

Hematology Division, Chaim Sheba Medical Centre, Tel-Hashomer, Israel.

Tammy Hod (T)

Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
Nephrology Department, Chaim Sheba Medical Centre, Tel-Hashomer, Israel.

Noam Erez (N)

Department of Infectious Diseases, Israel Institute for Biological Research, Ness-Ziona, Israel.

Itzhak Levy (I)

Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
The Infectious Disease Unit, Chaim Sheba Medical Center, Tel-Hashomer, Israel.

Galia Rahav (G)

Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.
The Infectious Disease Unit, Chaim Sheba Medical Center, Tel-Hashomer, Israel.

Abraham Avigdor (A)

Hematology Division, Chaim Sheba Medical Centre, Tel-Hashomer, Israel.
Sackler Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH